Brain areas and pathways in the regulation of glucose metabolism

Diepenbroek, Charlene; Serlie, Mireille J.; Fliers, Eric; Kalsbeek, Andries; Fleur, Susanne E. la

doi:10.1002/biof.1123

Cited by 12 publications

(9 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The brain uses mainly glucose to obtain the energy needed to function correctly [55]. A recent study describes that there is a significant correlation between the cerebral metabolic rate of glucose, measured by FDG PET, and the level of consciousness in patients in a vegetative or minimally conscious state, with the metabolic rate of glucose being capable of differentiating between both conditions [56].…”

Section: Discussionmentioning

confidence: 99%

Treatment with Growth Hormone (GH) Increased the Metabolic Activity of the Brain in an Elder Patient, Not GH-Deficient, Who Suffered Mild Cognitive Alterations and Had an ApoE 4/3 Genotype

Devesa¹,

Núñez²,

Agra³

et al. 2018

IJMS

View full text Add to dashboard Cite

(1) Background: We analyzed, using PET-SCAN and cognitive tests, how growth hormone (GH) could act in the brain of an older woman, not deficient in GH, who showed mild cognitive alterations (MCI) and had a genotype of ApoE 4/3 and familial dyslipidemia. (2) Methods: After performing a first psychometric study (TAVEC verbal learning test), the metabolic activity of brain structures related to knowledge, memory, and behavior was analyzed using 18-F fluorodeoxyglucose PET-SCAN. The patient was then treated with GH (0.4 mg/day, subcutaneous) for three weeks and on the last day under this treatment, a new PET-SCAN was performed. One month after beginning treatment with GH, a new TAVEC test was performed. (3) Results: GH administration normalized the cognitive deficits observed in the first psychometric test and significantly (p < 0.025) increased the metabolic activity in practically all brain cortical areas, specifically in the left hippocampus and left amygdala, although not in the left parahippocampus. (4) Conclusions: This study demonstrates for the first time the positive effects of GH on cerebral metabolism in a patient without GH deficiency, recovering the function of affected areas related to knowledge, memory, and behavior in an elderly patient with MCI.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with Growth Hormone (GH) Increased the Metabolic Activity of the Brain in an Elder Patient, Not GH-Deficient, Who Suffered Mild Cognitive Alterations and Had an ApoE 4/3 Genotype

Devesa¹,

Núñez²,

Agra³

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…To date, the role of the sNAc in the regulation of glucose metabolism has received little attention whereas its role in food-motivated behavior is well established (Diepenbroek et al, 2013). The effects of DBS, we present here, point toward a role for this nucleus in the response to hypoglycaemia.…”

Section: Discussionmentioning

confidence: 99%

Alterations in blood glucose and plasma glucagon concentrations during deep brain stimulation in the shell region of the nucleus accumbens in rats

Diepenbroek¹,

Plasse²,

Eggels³

et al. 2013

Front. Neurosci.

Self Cite

View full text Add to dashboard Cite

Deep brain stimulation (DBS) of the nucleus accumbens (NAc) is an effective therapy for obsessive compulsive disorder (OCD) and is currently under investigation as a treatment for eating disorders. DBS of this area is associated with altered food intake and pharmacological treatment of OCD is associated with the risk of developing type 2 diabetes. Therefore we examined if DBS of the NAc-shell (sNAc) influences glucose metabolism. Male Wistar rats were subjected to DBS, or sham stimulation, for a period of 1 h. To assess the effects of stimulation on blood glucose and glucoregulatory hormones, blood samples were drawn before, during and after stimulation. Subsequently, all animals were used for quantitative assessment of Fos immunoreactivity in the lateral hypothalamic area (LHA) using computerized image analysis. DBS of the sNAc rapidly increased plasma concentrations of glucagon and glucose while sham stimulation and DBS outside the sNAc were ineffective. In addition, the increase in glucose was dependent on DBS intensity. In contrast, the DBS-induced increase in plasma corticosterone concentrations was independent of intensity and region, indicating that the observed DBS-induced metabolic changes were not due to corticosterone release. Stimulation of the sNAc with 200 μA increased Fos immunoreactivity in the LHA compared to sham or 100 μA stimulated animals. These data show that DBS of the sNAc alters glucose metabolism in a region- and intensity- dependent manner in association with neuronal activation in the LHA. Moreover, these data illustrate the need to monitor changes in glucose metabolism during DBS-treatment of OCD patients.

show abstract

“…Development of the insulin-resistant state during these periods of seasonal change precisely mimics the type 2 diabetic state. At the end of the season, animals revert back to their insulin-sensitive state with correction of these metabolic abnormalities [37,43,44 ].…”

Section: Discussionmentioning

confidence: 99%

Co-Administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM

Morcos¹,

Ebeid²,

Khodeir³

et al. 2017

J Diabetes Metab

View full text Add to dashboard Cite

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agents with novel mechanisms of action is highly desirable. Cabergoline, D2 agonist, is expected to play a role in the glycemic control.Objective: Evaluation of the glycemic efficacy of cabergoline on diabetic patients.Design: Fifty type 2 diabetic patients participated in the study for four months; 25 patients receive gliclazide (60-120 mg) once daily and 25 patients receive cabergoline 0.5 mg twice weekly within 2 hrs of wakening plus gliclazide. 10 healthy people with matched age participated as a control group. Fasting and post prandial BG level were measuredmonthly. HbA1c, fasting insulin, HOMA IR and lipid profile were measured at baseline and after four months.Results: Treatment of the patients with cabergoline and gliclazide resulted in greater significant (p<0.05) decrease in FBG, PPBG, HbA1c compared treatment with gliclazide only. Insulin levels were reduced and insulin sensitivity was enhanced with improvement in lipid profile. Conclusion:Cabergoline is well-tolerated new antidiabetic line acting with a unique insulin sensitizing actions.

show abstract

Brain areas and pathways in the regulation of glucose metabolism

Cited by 12 publications

References 89 publications

Treatment with Growth Hormone (GH) Increased the Metabolic Activity of the Brain in an Elder Patient, Not GH-Deficient, Who Suffered Mild Cognitive Alterations and Had an ApoE 4/3 Genotype

Treatment with Growth Hormone (GH) Increased the Metabolic Activity of the Brain in an Elder Patient, Not GH-Deficient, Who Suffered Mild Cognitive Alterations and Had an ApoE 4/3 Genotype

Alterations in blood glucose and plasma glucagon concentrations during deep brain stimulation in the shell region of the nucleus accumbens in rats

Co-Administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM

Contact Info

Product

Resources

About